Loading stock data…
Ocular Therapeutix (OCUL)
$9.90+0.06 (+0.61%)
Market ClosedLast close Jun 29
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Ocular Therapeutix, Inc. in the Healthcare sector is trading at $9.90 with a market capitalization of $1.9B. Wall Street consensus targets $27.09 (11 analysts), implying a +173.6% move over the next 12 months. The stock is currently 40% below its 52-week high of $16.44, remaining 5.0% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. Risk note: RSI 79 is overbought against a weak tape. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +173.6% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Overbought RSI 79 against a weak tape — risk of pullback
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $10.79M↓ | $13.25M↓ | $14.54M↑ | $13.46M↑ | $10.70M |
| Gross Profit | $9.46M↓ | $11.66M↓ | $12.77M↑ | $11.52M↑ | $9.44M |
| Operating Income | -$93.34M↓ | -$69.76M↓ | -$68.70M↓ | -$67.64M↓ | -$63.92M |
| Net Income | -$88.61M↓ | -$64.65M↑ | -$69.42M↓ | -$67.81M↓ | -$64.05M |
Peer Comparison
JNJUNHPFE
Fundamentals
Ocular Therapeutix, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies for retinal diseases and other eye conditions using its bioresorbable hydrogel-based formulation technology in the United States. The...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.93B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-49.95%
Volume
Today's trading volume
2.01M
Recent News
Is Ocular Therapeuticx, Inc. (OCUL) Stock Positioned for Growth After Positive FDA Feedback on Axpaxli?
We recently compiled a list of the 10 Best Healthcare Stocks to Buy According to Wall Street Analysts. Ocular Therapeuticx, Inc. (NASDAQ:OCUL) is among the best healthcare stocks. TheFly reported on June 18 that H.C. Wainwright increased its price target on OCUL to $25 from $21 while maintaining a Buy rating on the stock. The firm’s […]
Ocular Therapeutix (OCUL): Buy, Sell, or Hold Post Q1 Earnings?
Over the past six months, Ocular Therapeutix’s shares (currently trading at $10.37) have posted a disappointing 18.5% loss, well below the S&P 500’s 7.8% gain. This was partly due to its softer quarterly results and might have investors contemplating their next move.
Stocks making big moves yesterday: Nubank, Ocular Therapeutix, Mondelez, ResMed, and Sonos
Check out the companies making headlines yesterday:
Why Ocular Therapeutix (OCUL) Stock Is Up Today
Shares of ophthalmology biopharmaceutical company Ocular Therapeutix (NASDAQ:OCUL) jumped 7.2% in the afternoon session after the company announced it reached an agreement with the U.S. Food and Drug Administration (FDA) on a plan to submit a New Drug Application (NDA) for its AXPAXLI injection.
OCUL Stock Is Climbing Ahead Of Investor Day — What Is On The Agenda?
Ocular said its U.S. Food and Drug Administration-aligned New Drug Application for wet age-related macular degeneration therapy is expected to be submitted in the fourth quarter of 2026.